Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      Home
      /
      Oncology
      /
      Interventional Oncology
      /
      INTO External Innovation team

      Meet the Interventional Oncology External Innovation team

      We are seeking external innovations to further our intratumoral portfolio.
      • Stephen Pitt

        Stephen Pitt, Ph.D.

        Global Head, External Innovation, Interventional Oncology
      • Ann Ballesteros, Ph.D.

        Ann Ballesteros, Ph.D.

        Director, Alliance Management, Interventional Oncology
      • Kai Stoeber, Ph.D.

        Kai Stoeber, Ph.D.

        External Innovation Lead, EMEA, Interventional Oncology

      Key areas of interest

      At Interventional Oncology, we believe developing new intratumoral and local therapies will help transform the standard of care for cancer patients. Our areas of interest include:

      Cytotoxic agents

      Drugs with enhanced cytotoxic activity and drug depot technologies/controlled release platforms

      Immune activating agents

      Pro-inflammatory cytokines and energy-based modalities that activate the immune system.

      Therapies that potentiate the effects of radiation

      Locally delivered or activated agents, and systemically delivered therapies that enhance local radiation therapy

      Platforms

      Drug delivery platforms for small molecules, nucleic acid delivery and protein delivery

      Procedure enablers

      Technologies used to plan, deliver, monitor, and confirm IT therapy delivery, as well as new models for local delivery

      Emerging and transformational intratumoral approaches

      Emerging technologies

      Contact us

      We are seeking external innovations to further our intratumoral portfolio. Contact us for partnership opporunities.
      Email us